Why is the epicenter of the diabetes epidemic shifting geographically?

Rapid urbanization and dietary changes in regions like the Middle East, Southeast Asia, and Latin America have led to an explosion in diabetes prevalence. In many of these nations, the infrastructure for chronic disease management is still maturing, creating both a public health crisis and a significant opportunity for pharmaceutical expansion.

What are the primary Emerging Market Diabetes Drug Trends in 2024?

Monitoring Emerging Market Diabetes Drug Trends reveals a move toward locally-manufactured generics and affordable biosimilars. In 2024, Western firms are increasingly utilizing licensing agreements with local manufacturers to bypass trade barriers and reach price-sensitive populations that were previously underserved.

How will market access improve in 2025?

By 2025, we expect to see more "Access-to-Medicine" programs that utilize tiered pricing models. Governments in emerging economies are also expanding their national insurance coverage to include modern analogs and GLP-1s, realizing that the cost of treating dialysis and blindness far outweighs the cost of the medications themselves.

2025 Market Outlook

The 2025 outlook predicts that over 50% of the growth in the global diabetes drug market will come from outside North America and Europe. Companies that establish robust distribution networks and cold-chain logistics in these regions will capture the first-mover advantage.

Author: Sofiya Sanjay

Designation: Healthcare Research Consultant, Market Research Future

About: At Market Research Future (MRFR), we enable organizations to unravel complex industries through Cooked Research Reports (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. Our studies across products, technologies, applications, end users, and global to country-level segments help decision-makers see more, know more, and do more.

Contact: 99 Hudson Street, 5th Floor, New York, NY 10013, USA | (855) 661-4441 (US) | +44 1720 412 167 (UK) | +91 2269738890 (APAC) | [email protected]